In Vitro Efficacy Testing Services for Inflammatory Bowel Disease

We provide robust and sensitive in vitro screening and characterization platforms for accelerating the discovery and screening of potential therapies for Inflammatory Bowel Disease (IBD). Our services offer comprehensive efficacy assessment of candidate compounds targeting critical pathways such as cytokine signaling, epithelial barrier integrity, and immune cell activation implicated in IBD. We focus on evaluating key proteins and biomarkers relevant to inflammation, mucosal healing, and immune dysregulation associated with this disease. Our assays enable the investigation of pathological processes including chronic inflammation, oxidative stress, and tissue damage characteristic of IBD.

Our in vitro testing services utilize a diverse range of assay platforms, including fluorescence-based assays, hemoglobin capture assays, and RNA quantification assays. These methodologies enable precise measurement of cellular responses, biomarker expression, and functional outcomes to support therapeutic discovery and optimization. Each method is tailored to assess specific aspects of IBD pathology and drug action.

Fluorescent assay: Employs fluorescent markers to detect and quantify cellular events, such as cytokine production or cell viability, providing real-time and high-throughput data relevant to inflammatory responses in IBD.

Hemoglobin capture assay: Measures hemoglobin levels as an indicator of epithelial barrier disruption or bleeding, enabling assessment of tissue integrity and mucosal damage under inflammatory conditions.

RNA assay: Quantifies changes in gene expression of key inflammatory mediators or biomarkers, allowing evaluation of molecular effects and pathway modulation by test compounds.

We measure a comprehensive set of pharmacological parameters to assess compound potency, efficacy, and safety profiles. These include concentration-based metrics that inform on the minimal effective and inhibitory concentrations, which are crucial for therapeutic development and optimization. Accurate parameter determination facilitates informed decision-making in lead selection and dose determination.

EC-50: The concentration of a compound that produces 50% of its maximal effect, indicating potency and helping to compare relative efficacy among candidates.

IC-50: The concentration required to inhibit a specific biological function or biomarker by 50%, which is critical for evaluating the inhibitory potential of anti-inflammatory agents.

MEC (Minimum Effective Concentration): The lowest concentration at which a compound demonstrates a desired biological effect, essential for establishing therapeutic windows.

MIC (Minimum Inhibitory Concentration): The minimum concentration needed to inhibit the growth of relevant microorganisms or cells, providing important data on antimicrobial or cytostatic properties.

Recommended In Vitro Efficacy Tests

Nitric Oxide Synthase 2

Nitric Oxide Synthase 2 (NOS2) is upregulated in Inflammatory Bowel Disease (IBD), contributing to inflammation and tissue damage. NOS2 testing is critical for IBD drug development to assess compound efficacy in modulating this enzyme. Our service utilizes RNA assays and hemoglobin capture assays to quantify NOS2 activity, providing key pharmacological parameters including IC-50 and MIC for candidate therapeutics, thereby supporting informed decision-making in early-stage IBD drug discovery.

Transient Receptor Potential Cation Channel Subfamily M Member 8

The Transient Receptor Potential Cation Channel Subfamily M Member 8 (TRPM8) is implicated in inflammatory signaling pathways in Inflammatory Bowel Disease (IBD). TRPM8 testing is crucial for evaluating novel IBD therapeutics targeting this pathway. Our service utilizes a sensitive fluorescent assay to assess compound activity, providing key parameters such as Minimum Effective Concentration (MEC) and half-maximal effective concentration (EC-50) to support data-driven drug development decisions.